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Abstract The multicenter phase III preclinical trial concept is
currently discussed to enhance the predictive value of preclin-
ical stroke research. After public announcement, we collected
a community feedback on the concept with emphasis on po-
tential design features and guidelines by an anonymous sur-
vey. Response analysis was conducted after plausibility
checks by applying qualitative and quantitative measures.
Most respondents supported the concept, including the imple-
mentation of a centralized steering committee. Based on re-
ceived feedback, we suggest careful, stepwise implementation
and to leave selected competencies and endpoint analysis at
the discretion of participating centers. Strict application of
quality assurance methods is accepted, but should be harmo-
nized. However, received responses also indicate that the
application of particular quality assurance models may require
more attention throughout the community. Interestingly, clear
and pragmatic preferences were given regarding publication
and financing, suggesting the establishing of writing commit-
tees similar to large-scale clinical trials and global funding
resources for financial support. The broad acceptance among
research community encourages phase III preclinical trial
implementation.
Keywords Animal models . Experimental . Focal ischemia .
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BThere are many aspects to P3PT that are important
including quality standards, assessment criteria,
funding, data management, and choice of participating
centres. All of these will have to be rigorously thought
through, and dealt with before P3PT goes ahead.^ –
selected statement from an individual commenting on
the P3PT concept
Introduction
The concept of multicenter ‘phase III’ preclinical trials (P3PT)
for the evaluation of neuroprotective strategies is suggested to
overcome the translational roadblock in stroke research [1].
Importantly, it is not meant to replace exploratory scientific
work as usually performed by individual laboratories (‘phases
I and II’), but represents a type of confirmative research con-
ducted by collaborating centers [2]. P3PT should be
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performed prior to early stage clinical investigations and shall
contribute to the strongly desired predictive value increase in
stroke research.
Expert consortia are currently defining potential P3PT
frameworks and guidelines, including ways for their future
implementation. In parallel, a number of editorials, white pa-
pers, and commentaries have reviewed the concept. However,
such publications exclusively represent statements by groups
of selected experts or renowned individuals. While this pro-
vides well-thought through and highly relevant impulses ex-
pediting and refining the P3PT idea, it omits the chance to
include ideas and feedback from a broader audience.
The first P3PT has recently been completed [3], but wider
adoption and sustained utilization of the P3PT concept re-
quires acceptance throughout the community down to its
grassroots, i.e., junior investigators in smaller stroke research
laboratories, as well as technicians and students conducting
experiments everyday. Hence, the currently ongoing, expert
consortia-based design of the P3PT framework might benefit
from sensory input from a diverse audience representing the
wider stroke research community without balancing towards a
specific subgroup.
Collecting a Community Feedback on the P3PT
Concept
We sought community feedback on the P3PT concept by a
public call for an online questionnaire which was announced
in a previous publication [4]. The roster contained single (SA)
and multiple answer (MA) questions plus five free text an-
swers (see supplementary information). It was hosted by
SoSci Survey (Munich, Germany) for 6 months. Answers
were assessed for repeated access to avoid bias from counting
multiple, but similar and potentially extreme statements.
Received information was further subjected to a plausibility
check to ensure information consistency (see supplementary
material for details). Only those contributions addressing an a
priori defined minimum of one survey section were included
in the final analysis. An exception was a negative statement
regarding general acceptance of the P3PT concept (first ques-
tion), which was recorded even in case no further question
was answered to prevent missing any potential negative state-
ments on the concept. All survey questions, methodological
details on the feedback acquisition strategy and data analysis
are given in the supplementary material, which also contains
complete collection of all free text answers.
Of note, the survey was designed as a completely anony-
mous platform and did not weight individual contributions by
the responder’s level of responsibility, experience, or visibility
in the field. Nevertheless, the feedback received on the free
text answers suggests that a significant proportion of individ-
uals responding to our call are experienced scientists, having
profound experience with clinical research, and/or oversee a
wide spectrum of research activities. A total of 93 contribu-
tions were considered for analysis based on aforementioned
plausibility checks, with 81 individuals completing the entire
survey.
The Community View on P3PT Organization
and Quality Assurance
Overall acceptance of the P3PT concept was very high
(Fig. 1a). Only 10 % questioned the concept while 90 % ac-
knowledged at least a theoretical benefit. Respondents found a
clear and significant overall benefit, recommending to test the
concept at a limited scale initially, or assumed it hard to im-
plement but acknowledged its theoretical value (16 % each).
The majority (42 %, p < 0.05) requested a careful implemen-
tation to ensure maximum benefit. We support this position
because careful and potentially stepwise implementation of
the concept is warranted in order to investigate which organi-
zational items provide the best balance between practicability
and study design complexity, and mitigate the risk of larger
failures.
The application of high quality standards seems mandatory
to ensure a maximum benefit from P3PT. Accordingly, most
participants recommended restricting P3PT projects to centers
evidently applying quality standards (40 %, see below for
implementation-specific standards), or even to pre-selected
labs (33 %, Fig. 1a). This would, however, exclude smaller
and less experienced laboratories from P3PT projects at least
in initial stages.
A centrally determined study protocol for each lab (33 %)
was not recommended statistically more often over
decentralized monitoring approaches or strict centralized sur-
veillance (Fig. 1b). Most participants preferred a common
study design with pre-set endpoints for all participating cen-
ters. This indicates a high awareness for standardization with-
in P3PT. However, a majority of participants (44 %) also ad-
vocated for a design which, next to addressing centrally deter-
mined endpoints according to a common plan, allows addi-
tional endpoints to be investigated by individual labs (p <
0.05; Fig. 1b). This suggestion is remarkable since it offers
an option to capitalize on benefits from a centralized study
organization (e.g., reliable study results on primary endpoints)
without omitting the possibility to receive valuable secondary
endpoint data by utilizing individual lab competencies.
Although the assessment of such secondary endpoints is sta-
tistically less powerful due to the smaller number of subjects/
cases investigated, overall information content and translation-
al relevance are likely to be increased. Importantly, this also
underpins the importance of academic centers as the main
stakeholders in P3PTs because other well organized and
equipped entities such as commercial contract research
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organizations often cannot offer a similar diversity of available
methods and readout assays. No clear preference was given for
data analysis, but centralized data analysis (29 %) or at least
analysis surveillance (27%)were selectedmost often (Fig. 1b).
Application of minimum quality assurance criteria plus a
pre-defined experimental plan applying to each lab (39 %), or
even restricting participating labs to those applying ARRIVE
(http://www.nc3rs.org/ARRIVE) or STAIR [5] criteria
recommendations (31 %; p < 0.05 each), were considered
superior to intra-lab quality assurance (Fig. 1c). Official agree-
ment on quality assurance criteria by all partners (43 %) and
standardized experimenter training (38 %) were superior to all
other options, including pre-study round robin trials for qual-
ity check-up (13 %; p < 0.05 each; Fig. 1c).
Fig. 1 Feedback on P3PTorganization and quality assurance as provided by survey participants. a, b provide answer frequency on questions regarding
organization while c shows community statements regarding quality standards and their assurance in P3PTs. *p < 0.05
Transl. Stroke Res.
P3PT Methodology
Each aspect suggested for intra-experimental quality assur-
ance was at least recommended by 60 %, with blinding/
randomization (69 %/72 %) and definition of exclusion/
inclusion criteria (80 %) being selected most frequently. All
were considered superior to omitting standardization
(p < 0.05; Fig. 2a). Appropriate positive/negative controls
were recommended most frequently for the experimental de-
sign (76 %; Fig. 2a), corroborating a clear community affir-
mation to quality assurance principles.
However, 31 % did not put special emphasis on blinding
and/or randomization. This is a striking finding since (i)
neglecting these aspects has been discussed to contribute to
the translational failure in stroke research and (ii) blinding to
avoid bias is an essential, uniformly adopted approach in clin-
ical trials. The picture was also less consistent when it came to
monitoring of important physiological parameters. Recording
of body weight and temperature during surgery was found
recommendable by most responders (80 %) while cerebral
blood flow (CBF) monitoring to ensure stroke induction was
not considered as important by 38 % of the participants.
Although stroke induction can be monitored by alternative
methods such as magnetic resonance imaging, those are tech-
nically more complex and less widely available. From our
perspective, this indicates a need for a broader awareness of
the necessity to thoroughly control stroke induction. Even
fewer participants (53 %) considered arterial blood gases/pH
monitoring during surgery to be necessary despite recommen-
dations that thorough monitoring of blood chemistry parame-
ters is critical to ensure result reliability in stroke research [5].
In summary, considering these key methodological aspects
will be critical to ensure maximum predictability of P3PT
studies. This likely requires increased awareness throughout
the community or even mandatory.
Testing of therapeutic efficacy in aged versus young (76 %),
male versus female (75 %), and in comorbid (73 %) rodent
species were recommended most often to enhance the predic-
tive value of P3PT (p < 0.05 each; Fig. 2c). Surprisingly, only
55 % considered investigation of at least two species, a central
recommendation of the STAIR expert consortium [5].
Conducting large animal experiments (39 %) and considering
polypharmacy (37 %) were recommended least often. This is
understandable given the complexity of appropriate model sys-
tems and their limited availability. Nevertheless, studies utiliz-
ing large animal and polypharmacy models are important for a
number of reasons. Large animal models may provide an ad-
ditional benefit in the assessment of novel stroke therapies with
respect to brain anatomy (gyrencephalic species) and potential
distribution aspects of a pharmacological treatment (larger
brain) [6] with primate models being the main expert recom-
mendation [7]. Polypharmacy is a frequent observation in hu-
man stroke patients and an interaction between an experimental
therapeutic and the patient’s medication is relatively likely [2].
Being hard to investigate by most single centers, P3PT may
offer a practicable framework to address these aspects. The
same applies to the heterogeneity of strokes often seen in clin-
ical trials but rarely represented in experimental studies.
Consequently, the use of multiple stroke models to reflect pa-
tient heterogeneity was found more useful than the reliance on
any specific stroke model (67 %; p < 0.05; Fig. 2c).
Special emphasis was given on post-stroke care and preset
exclusion/inclusion criteria with half of the participants also
pointing at factors such as nutrition and fluid supply (Fig. 2c).
Accordingly, participating colleagues also called for mimick-
ing clinically realistic scenarios such as combination with tPA,
body weight/surface-based dosing, and i.v. administration of
the therapeutic agent when testing a therapeutic paradigm.
Using same dose in all animals (3 %) or selecting administra-
tion protocols promising best effect size (28 %) were consid-
ered inferior approaches (p < 0.05; Fig. 2c).
P3PT Financing and Publication
Financing and publication represent challenges in large scale
preclinical studies. Although we expected a heterogeneous opin-
ion spectrum, clear statements were provided by the community.
The most popular option for publication was that study initiators
should cover first and/or senior author positions and/or invite
members of the writing committee, with all other experimenters
listed as co-authors/contributors (43 %; p < 0.05; Fig. 2d). This
supports the idea of formingwriting committees as proven useful
for large-scale clinical trials. Importantly, balancing transparency
versus justified background interests (patents, technological
knowhow) will require individual solutions, which should be
informed by good practice in clinical trials.
Using (still non-existing) global funding schemes was
found to be the most appropriate approach for P3PT financ-
ing (86 %; p < 0.05; Fig. 2d). This is consistent with the
fact that stroke is a global burden requiring mobilization of
global resources to counter it. Requesting industrial support
was recommended by 63 % and is warranted since the
pharmaceutical industry is expected to benefit, e.g., from
concept falsification by P3PTs prior to significant reputa-
tional and financial losses in failed clinical trials [8].
Nevertheless, realization of global funding mechanisms
may be hard to achieve while potential conflicts and intel-
lectual property issues arising within academic-industrial
Fig. 2 Feedback P3PT methodology, financing and result publication. a
to c provide answer frequencies on questions regarding numerous central
aspects of P3PT methodology. Abbreviations are as follows: HTN
hypertension, DM diabetes mellitus, HL hyperlipidemia, d distal, e
embolic, f filament middle cerebral artery occlusion (MCAO). d shows




partnerships demand careful consideration. Collaboration
between leaders from basic research, industry, and regula-
tory authorities as previously proven beneficial [5] may be
required to orchestrate P3PT realization.
Information Derived from Free Text Answers
When categorizing answers regarding content and counting
for answers referring to the particular aspect, three major
points of interested within the participant community became
evident: (i) implementation of very high quality standards in
P3PT (n = 7), (ii) careful selection of endpoints, models, and
participating labs while at the same time ensuring high inter-
action among P3PT participants (n = 10) as well as (iii) orga-
nizing P3PT close to the design of late stage clinical trials
(n = 11) was particularly stressed.
Limitations of the Survey
As with any voluntary participation in opinion surveys, scien-
tists who are less supportive of the P3PT concept may not have
taken the time to contribute their thoughts to our or other initia-
tives and thus potentially bias our results. However, it is equally
possible that those who are not supportive of the P3PT idea
could have taken this anonymous opportunity to express their
opinions by answering the survey. We did not collect informa-
tion regarding respondents’ positions (e.g., senior vs. junior) or
their actual participation in preclinical stroke research and drug
testing. This impedes weighting of feedbacks and positions pro-
vided with respect to experience and level of expertise of the
respective respondent. On the other hand, the strictly anony-
mous nature may have helped to receive a broader feedback
from the stroke community, which is critical for the acceptance
and large-scale implementation of the P3PT concept.
Conclusions
Despite its limitations, our survey provides profound feedback
from a considerable number of individual respondents. Their
feedback encourages further steps implementing P3PTstudies
into translational research strategies, but also highlights con-
troversies around specific aspects of its implementation.
Based on the analysis of received answers, we suggest
Table 1 Conclusions and recommendations for the implementation of P3PT based on community feedback analysis
Area Conclusion/recommendation Benefit
P3PT implementation Careful and stepwise implementation recommended Widespread acceptance more likely
Initial preclinical multicenter studies should be
performed by experienced centers, ideally
having a long-standing history of collaboration
Swift and exact estimation of P3PT
benefit under practical conditions
P3PT organization and governance Centralized study governance and central study protocol Clinical-trial like design, enhanced
result comparability
Core endpoints addressed by all centers according
to P3PT protocol
Enhanced statistical power and higher
predictability for primary endpoints
Additional: individual endpoints addressed
by single centers with outstanding competencies
Broad spectrum of translationally
endpoints addressable (but no
benefit for study power)
P3PT animal models Use of multiple models, if applicable Better representation of patient population
(polypharmacy, age, sex, comorbidities)
Use of large animal models, if available Reflecting gyrencephalic brain structure,
closer similarity to human situation
P3PT quality assurance Further enhancing awareness for those (might require
institutional support [9])
Increasing scientific rigor and result
comparability, reducing divergences
in relevance acknowledgment throughout
the community
Strict application of quality assurance criteria Enhanced result comparability and relevance
P3PT financing and result publication Establishing and recruiting of global funds International and -continental collaboration
facilitated, reduced financial burden for
national public funding authorities
Early enrolment of high-quality academic-industry
collaborations
Timely involvement of key stakeholders,
preventing failure of clinical trials,
bolstering financial resources for P3PT
Establishing centralized writing committees More efficient workflow, comparability to
large scale clinical trials
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drawing the following conclusions and recommendations
with respect to five core areas (Table 1).
Since the P3PT idea can only be successful if supported by
the entire stroke research community, input from other initia-
tives and expert committees such as the MULTIPART project
(http://www.dcn.ed.ac.uk/multipart/default.htm) responding to
our results are essential and helpful to shape P3PT
implementation and to ensure its maximumbenefit and impact.
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